Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG035
MIFTS: 41

Lung Large Cell Carcinoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lung Large Cell Carcinoma

About this section

MalaCards integrated aliases for Lung Large Cell Carcinoma:

Name: Lung Large Cell Carcinoma 12 15
Large Cell Carcinoma of Lung 12 74
Large Cell Lung Carcinoma 12 17
Large Cell Lung Cancer 56

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Respiratory diseases Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4556
NCIt 51 C4450
UMLS 74 C0345958
Sources

Summaries for Lung Large Cell Carcinoma

About this section
MalaCards based summary : Lung Large Cell Carcinoma, also known as large cell carcinoma of lung, is related to pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with rhabdoid phenotype. An important gene associated with Lung Large Cell Carcinoma is ROS1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase), and among its related pathways/superpathways is Tyrosine Kinases / Adaptors. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and heart, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Large-cell carcinoma (LCC) is a heterogeneous group of undifferentiated malignant neoplasms that lack... more...

Sources

Related Diseases for Lung Large Cell Carcinoma

About this section

Diseases in the Lung Large Cell Carcinoma family:

Small Cell Cancer of the Lung Lung Clear Cell Carcinoma

Diseases related to Lung Large Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 26)
# Related Disease Score Top Affiliating Genes
1 pulmonary large cell neuroendocrine carcinoma 31.9 ROS1 SYP
2 large cell carcinoma with rhabdoid phenotype 11.9
3 lung cancer 11.6
4 lung mixed small cell and squamous cell carcinoma 11.4
5 large cell neuroendocrine carcinoma 11.1
6 large cell carcinoma 10.4
7 subependymal glioma 10.1 MTOR SYP
8 benign ependymoma 10.1 MTOR SYP
9 subependymal giant cell astrocytoma 10.0 MTOR SYP
10 central nervous system benign neoplasm 10.0 MTOR SYP
11 thymus gland disease 9.9 MTOR TTN
12 thrombocytosis 9.8
13 reflex sympathetic dystrophy 9.8
14 polyarteritis nodosa, childhood-onset 9.8
15 dermatomyositis 9.8
16 algoneurodystrophy 9.8
17 neuroendocrine carcinoma 9.8
18 calcinosis 9.8
19 inner ear disease 9.8
20 vasculitis 9.8
21 polyarteritis nodosa 9.8
22 autoimmune inner ear disease 9.8
23 pulmonary sequestration 9.8
24 myxosarcoma 9.8 NME1 SYP
25 geographic tongue 9.7 MTOR NME1
26 malignant pheochromocytoma 9.7 NME1 SYP

Graphical network of the top 20 diseases related to Lung Large Cell Carcinoma:



Diseases related to Lung Large Cell Carcinoma
Sources

Symptoms & Phenotypes for Lung Large Cell Carcinoma

About this section

GenomeRNAi Phenotypes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

27 (show top 50) (show all 53)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.22 MTOR
2 Decreased viability GR00221-A-1 11.22 MTOR ROS1 RPS6KA6 BTK NME1 TRPM6
3 Decreased viability GR00221-A-2 11.22 ROS1 TTN EPHA5 RPS6KA6 BTK NME1
4 Decreased viability GR00221-A-3 11.22 EPHA5 BTK CDC42BPB LATS1
5 Decreased viability GR00221-A-4 11.22 MTOR TTN EPHA5 RPS6KA6 BTK CDC42BPB
6 Decreased viability GR00301-A 11.22 BTK LATS1
7 Decreased viability GR00342-S-1 11.22 MTOR ROS1 TTN
8 Decreased viability GR00342-S-2 11.22 MTOR RPS6KA6
9 Decreased viability GR00342-S-3 11.22 TTN EPHA5 RPS6KA6
10 Decreased viability GR00402-S-2 11.22 MTOR ROS1 TTN EPHA5 RPS6KA6 BTK
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.31 TRRAP
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.31 WNK3
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.31 MTOR
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.31 WNK3
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.31 TRRAP
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 10.31 TRRAP WNK3
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.31 MTOR
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 10.31 BTK
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.31 BTK MTOR TRRAP WNK3
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.31 TRRAP
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.31 TRRAP
22 Decreased substrate adherent cell growth GR00193-A-1 10.14 BTK ROS1 TTN
23 Decreased substrate adherent cell growth GR00193-A-2 10.14 ROS1 LATS1 MTOR TRRAP WNK3
24 Decreased substrate adherent cell growth GR00193-A-4 10.14 BTK
25 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.13 BTK
26 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.13 MTOR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.13 MTOR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.13 TRRAP
29 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.13 NME1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.13 WNK3
31 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.13 BTK
32 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.13 NME1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.13 BTK
34 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.13 BTK
35 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.13 MTOR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.13 NME1 TRRAP
37 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.13 TRRAP
38 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.13 TRRAP
39 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.13 BTK WNK3
40 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.13 WNK3
41 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.13 BTK
42 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.13 MTOR
43 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.13 NME1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-69 10.13 WNK3
45 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.13 BTK MTOR
46 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.13 BTK MTOR NME1 TRRAP WNK3
47 Increased shRNA abundance (Z-score > 2) GR00366-A-97 10.13 NME1
48 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.93 CDC42BPB MTOR NME1 RPS6KA6 TRRAP TTN
49 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.88 BTK LATS1 MTOR TRRAP WNK3
50 Decreased vesicular stomatitis virus (VSV) infection GR00356-A-1 9.67 MTOR TRPM6 TRRAP TTN
Sources

Drugs & Therapeutics for Lung Large Cell Carcinoma

About this section

Drugs for Lung Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
2
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 6436030 5284616
5
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
6 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1
9 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Antibiotics, Antitubercular Phase 4,Phase 1,Phase 2
14 Antifungal Agents Phase 4
15
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
16
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
17
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
18
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
19
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
20
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
21
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 216974-75-3
22
Etoposide Approved Phase 3,Phase 1,Phase 2 33419-42-0 36462
23
Vinblastine Approved Phase 3 865-21-4 13342 241903
24
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
25
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
26
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
27
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
28
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
29
Crizotinib Approved Phase 3,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
30
nivolumab Approved Phase 3,Phase 2 946414-94-4
31
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
33
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
34 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
35
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
36 Antibodies Phase 2, Phase 3,Phase 3,Phase 1
37 Antibodies, Monoclonal Phase 2, Phase 3,Phase 3,Phase 1
38 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 3,Phase 1
39 Immunoglobulins Phase 2, Phase 3,Phase 3,Phase 1
40 Antiviral Agents Phase 3,Phase 2,Phase 1
41 Antimetabolites Phase 3,Phase 2,Phase 1
42 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
43 Hematinics Phase 3,Phase 2
44 Vitamin B Complex Phase 3,Phase 2,Phase 1
45 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
46 Vitamin B9 Phase 3,Phase 2,Phase 1
47 Folate Phase 3,Phase 2,Phase 1
48 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 3,Phase 1
49 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
50 Etoposide phosphate Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 152)
# Name Status NCT ID Phase Drugs
1 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
2 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
3 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
4 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
5 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
6 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
7 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
8 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
9 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3 carboplatin;paclitaxel
10 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
11 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
12 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
13 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
14 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
15 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
16 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
17 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
18 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3 carboplatin;paclitaxel
19 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
20 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
21 Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting NCT02194738 Phase 3 Crizotinib;Erlotinib Hydrochloride
22 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients Active, not recruiting NCT00030771 Phase 3 Chemotherapy
23 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
24 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
25 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
26 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
27 Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
28 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
29 Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
30 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
31 Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer Withdrawn NCT00055887 Phase 3 carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate
32 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
33 Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Unknown status NCT00616499 Phase 2 gefitinib
34 Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Unknown status NCT00003562 Phase 2 carboplatin;docetaxel
35 Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer Unknown status NCT00075517 Phase 2 docetaxel;gemcitabine hydrochloride
36 Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Unknown status NCT00006116 Phase 2 cisplatin;gemcitabine hydrochloride
37 Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT01024712 Phase 2 carboplatin;gefitinib;paclitaxel
38 Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Unknown status NCT00227708 Phase 2 docetaxel
39 Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Unknown status NCT00033722 Phase 2 lometrexol
40 Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
41 Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Completed NCT01642251 Phase 1, Phase 2 Cisplatin;Etoposide;Veliparib;Placebo
42 Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00003231 Phase 2 cisplatin;docetaxel
43 Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC Completed NCT00030810 Phase 2 Taxotere/Cisplatin
44 Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer Completed NCT00960999 Phase 2
45 MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
46 S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer Completed NCT00087412 Phase 2 erlotinib hydrochloride
47 Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial). Completed NCT01116219 Phase 2 bevacizumab, pemetrexed, cisplatin
48 Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer Completed NCT00003666 Phase 2 6-hydroxymethylacylfulvene
49 Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer Completed NCT00006877 Phase 2 temozolomide
50 Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function Completed NCT00002624 Phase 2

Search NIH Clinical Center for Lung Large Cell Carcinoma

Sources

Genetic Tests for Lung Large Cell Carcinoma

About this section
Sources

Anatomical Context for Lung Large Cell Carcinoma

About this section

MalaCards organs/tissues related to Lung Large Cell Carcinoma:

42
Lung, Brain, Heart, Testes, Lymph Node, Endothelial
Sources

Publications for Lung Large Cell Carcinoma

About this section

Articles related to Lung Large Cell Carcinoma:

(show all 12)
# Title Authors Year
1
Oxidative stress associates with aggressiveness in lung large-cell carcinoma. ( 25638031 )
2015
2
Large cell carcinoma of lung: On the verge of extinction? ( 25023633 )
2014
3
Rhabdoid large cell carcinoma of lung, with illustrative immunohistochemical and molecular findings. ( 22505007 )
2012
4
Toona sinensis extracts induced cell cycle arrest and apoptosis in the human lung large cell carcinoma. ( 20123594 )
2010
5
Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model. ( 20077433 )
2010
6
Lung large cell carcinoma producing granulocyte-colony-stimulating factor. ( 17184692 )
2007
7
Bilateral adrenal metastases from large cell carcinoma of lung in a female non-smoker patient. ( 16912999 )
2006
8
Solitary adrenal metastasis in large cell carcinoma of lung. ( 15558361 )
2004
9
Primary lung large cell carcinoma metastatic to the vulva: a case report and review of the literature. ( 15350382 )
2004
10
Large cell carcinoma of lung with osteoclast-like giant cells. ( 9639130 )
1998
11
High-dose tamoxifen reverses drug resistance to cisplatin and etoposide in a patient with advanced large cell carcinoma of lung. ( 9137495 )
1997
12
Establishment and characterization of a cell line, KaMi, from human lung large cell carcinoma. ( 1279943 )
1992
Sources

Variations for Lung Large Cell Carcinoma

About this section

Cosmic variations for Lung Large Cell Carcinoma:

9 (show top 50) (show all 732)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6953383 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 0
2 COSM6966579 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 0
3 COSM6980872 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1142C>T p.P381L 11:102229729-102229729 0
4 COSM95548 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 0
5 COSM95544 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 19:43546970-43546970 0
6 COSM6980399 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.233G>A p.W78* 11:32434909-32434909 0
7 COSM6938307 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1156A>T p.K386* 11:32392044-32392044 0
8 COSM95531 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.368G>C p.G123A 5:138088927-138088927 0
9 COSM95521 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 12:48966259-48966259 0
10 COSM21262 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 23:54236967-54236967 0
11 COSM95485 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 0
12 COSM95476 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 0
13 COSM96265 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64I 17:60301699-60301699 0
14 COSM94159 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.1555A>G p.S519G 8:102326590-102326590 0
15 COSM94158 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.2691A>T p.Q897H 8:102305221-102305221 0
16 COSM6983597 U2AF1 lung,NS,carcinoma,undifferentiated carcinoma c.319G>C p.D107H 21:43095467-43095467 0
17 COSM95420 TYK2 lung,NS,carcinoma,undifferentiated carcinoma c.3560G>T p.C1187F 19:10350838-10350838 0
18 COSM12945 TTBK1 lung,NS,carcinoma,large cell carcinoma c.2417C>T p.S806F 6:43283157-43283157 0
19 COSM6942934 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.1922C>T p.S641L 14:81143980-81143980 0
20 COSM6953382 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.937A>C p.K313Q 14:81142995-81142995 0
21 COSM6966576 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.412C>T p.L138F 14:81091088-81091088 0
22 COSM6980873 TSC2 lung,NS,carcinoma,undifferentiated carcinoma c.1840G>T p.A614S 16:2071510-2071510 0
23 COSM6980394 TSC1 lung,NS,carcinoma,undifferentiated carcinoma c.694G>T p.E232* 9:132921406-132921406 0
24 COSM12943 TRRAP lung,NS,carcinoma,large cell carcinoma c.8015C>T p.P2672L 7:98976613-98976613 0
25 COSM12942 TRPM6 lung,NS,carcinoma,large cell carcinoma c.3021G>C p.W1007C 9:74782752-74782752 0
26 COSM6980408 TRAF7 lung,NS,carcinoma,undifferentiated carcinoma c.1193C>T p.P398L 16:2173978-2173978 0
27 COSM6940747 TRAF7 lung,NS,carcinoma,undifferentiated carcinoma c.1287C>G p.Y429* 16:2174274-2174274 0
28 COSM95390 TRAF5 lung,NS,carcinoma,undifferentiated carcinoma c.302G>C p.R101T 1:211356392-211356392 0
29 COSM10808 TP53 lung,NS,carcinoma,large cell carcinoma c.488A>G p.Y163C 17:7675124-7675124 0
30 COSM10779 TP53 lung,NS,carcinoma,large cell carcinoma c.818G>T p.R273L 17:7673802-7673802 0
31 COSM43963 TP53 lung,NS,carcinoma,large cell carcinoma c.396G>C p.K132N 17:7675216-7675216 0
32 COSM6932 TP53 lung,NS,carcinoma,large cell carcinoma c.733G>A p.G245S 17:7674230-7674230 0
33 COSM10887 TP53 lung,NS,carcinoma,large cell carcinoma c.833C>G p.P278R 17:7673787-7673787 0
34 COSM11188 TP53 lung,NS,carcinoma,large cell carcinoma c.412G>C p.A138P 17:7675200-7675200 0
35 COSM21593 TP53 lung,NS,carcinoma,large cell carcinoma c.358A>T p.K120* 17:7676011-7676011 0
36 COSM10770 TP53 lung,NS,carcinoma,large cell carcinoma c.1045G>T p.E349* 17:7670664-7670664 0
37 COSM11333 TP53 lung,NS,carcinoma,large cell carcinoma c.499C>T p.Q167* 17:7675113-7675113 0
38 COSM11232 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.842A>G p.D281G 17:7673778-7673778 0
39 COSM43871 TP53 lung,NS,carcinoma,large cell carcinoma c.746G>T p.R249M 17:7674217-7674217 0
40 COSM45304 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.375+1G>A p.? 17:7675993-7675993 0
41 COSM10726 TP53 lung,NS,carcinoma,large cell carcinoma c.856G>A p.E286K 17:7673764-7673764 0
42 COSM10768 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.535C>T p.H179Y 17:7675077-7675077 0
43 COSM11564 TP53 lung,NS,carcinoma,large cell carcinoma c.742C>G p.R248G 17:7674221-7674221 0
44 COSM10659 TP53 lung,NS,carcinoma,large cell carcinoma c.817C>T p.R273C 17:7673803-7673803 0
45 COSM11196 TP53 lung,NS,carcinoma,large cell carcinoma c.734G>T p.G245V 17:7674229-7674229 0
46 COSM10810 TP53 lung,NS,carcinoma,large cell carcinoma c.725G>T p.C242F 17:7674238-7674238 0
47 COSM11392 TP53 lung,NS,carcinoma,large cell carcinoma c.800G>C p.R267P 17:7673820-7673820 0
48 COSM10648 TP53 lung,NS,carcinoma,large cell carcinoma c.524G>A p.R175H 17:7675088-7675088 0
49 COSM10742 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.578A>G p.H193R 17:7674953-7674953 0
50 COSM43559 TP53 lung,NS,carcinoma,large cell carcinoma c.517G>T p.V173L 17:7675095-7675095 0
Sources

Expression for Lung Large Cell Carcinoma

About this section
Search GEO for disease gene expression data for Lung Large Cell Carcinoma.
Sources

Pathways for Lung Large Cell Carcinoma

About this section

Pathways related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Tyrosine Kinases / Adaptors 4
10.97 BTK EPHA5 ROS1
Sources

GO Terms for Lung Large Cell Carcinoma

About this section

Cellular components related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.28 BTK CDC42BPB LATS1 MTOR MYO18B NME1

Biological processes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular signal transduction GO:0035556 9.65 BTK CDC42BPB LATS1 RPS6KA6 WNK3
2 protein phosphorylation GO:0006468 9.65 BTK CDC42BPB EPHA5 LATS1 MTOR ROS1
3 protein autophosphorylation GO:0046777 9.54 BTK MTOR WNK3
4 peptidyl-tyrosine phosphorylation GO:0018108 9.46 BTK EPHA5 ROS1 TTN
5 peptidyl-tyrosine autophosphorylation GO:0038083 9.43 BTK ROS1
6 regulation of protein kinase activity GO:0045859 9.4 MTOR TTN
7 phosphorylation GO:0016310 9.4 BTK CDC42BPB EPHA5 LATS1 MTOR NME1
8 cardiac muscle fiber development GO:0048739 9.32 MYO18B TTN

Molecular functions related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 9.93 BTK CDC42BPB EPHA5 LATS1 MTOR NME1
2 protein kinase activity GO:0004672 9.91 BTK CDC42BPB EPHA5 LATS1 MTOR ROS1
3 protein serine/threonine kinase activity GO:0004674 9.87 CDC42BPB LATS1 MTOR RPS6KA6 TRPM6 TTN
4 identical protein binding GO:0042802 9.83 BTK MTOR NME1 SYP TTN
5 ATP binding GO:0005524 9.73 BTK CDC42BPB EPHA5 LATS1 MTOR MYO18B
6 magnesium ion binding GO:0000287 9.71 CDC42BPB LATS1 NME1 RPS6KA6
7 protein tyrosine kinase activity GO:0004713 9.67 BTK EPHA5 ROS1 TTN
8 kinase activity GO:0016301 9.4 BTK CDC42BPB EPHA5 LATS1 MTOR NME1
Sources

Sources for Lung Large Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....